SBI-183 / Axim Biotech - LARVOL DELTA

AXIM Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1 (GlobeNewswire) - "AXIM® Biotechnologies, Inc...announced...that the United States Patent and Trademark Office (USPTO) has issued the Company a new Notice of Allowance for a patent (Application No. 15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and metastasis....The licensed Technology includes SBI-183, which is covered by this patent. SBI-183 selectively targets QSOX1 and, in animal models, has been found to inhibit tumor growth, invasion and suppress metastasis of tumors by inactivating QSOX1."

Patent • Oncology

[VIRTUAL] Chemical inhibitors of quiescin sulfhydryl oxidase (QSOX1) suppress tumor invasion and metastasis (AACR-II 2020) - "We previously reported that a small molecule, SBI-183, inhibited the enzymatic activity of QSOX1 and suppressed tumor cell invasion in vitro and metastasis of MDA-MB-231 breast tumor cells in vivo... Chemical inhibitors of QSOX1 have a minor effect on tumor cell viability, but a major effect on tumor cell invasion in vitro and metastasis in vivo. This finding suggests that combining a QSOX1 inhibitor with a cytotoxic agent might provide a means to inhibit metastasis of cells that are resistant to cytotoxic agents."

Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • QSOX1

Medical Marijuana, Inc. Investment Company AXIM Biotechnologies completes acquisition of Oncology Research and Development Company Sapphire Biotech, Inc. (PRNewswire) - "Medical Marijuana, Inc...announced...that its investment company AXIM® Biotechnologies, Inc...has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. ('Sapphire')....Sapphire has licensed a leading compound called SBI-183, which inhibits and suppresses invasion in vitro and metastasis in vivo."

M&A

AXIM Biotechnologies completes pre-clinical drug studies on new compound proving tenfold greater inhibition of tumor metastasis than parent compound (GlobeNewswire) - "AXIM^® Biotechnologies, Inc...announced....that its subsidiary Sapphire Biotech, Inc. ('Sapphire') has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis."

Preclinical

AXIM Biotechnologies completes acquisition of oncology research and development company Sapphire Biotech, Inc. (GlobeNewswire) - "AXIM® Biotechnologies, Inc...announced...that the Company has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. ('Sapphire')....Sapphire has licensed a leading compound, called SBI-183, which inhibits and suppresses invasion in vitro and metastasis in vivo."

M&A

AXIM Biotechnologies acquiree Sapphire Biotech, Inc. signs sponsored research agreement with Arizona State University to develop metastatic cancer inhibitor (GlobeNewswire) - "AXIM^® Biotechnologies, Inc...announced today that its acquiree Sapphire Biotech, Inc. ('Sapphire') has signed a Sponsored Research Agreement ('SRA') with Arizona State University ('ASU') to conduct preclinical studies using Quiescin Sulfhydryl Oxidase 1 ('QSOX1') inhibitors as anti-neoplastic compounds....SBI-183, part of Sapphire’s exclusively licensed Technology, has been proven to inhibit tumor growth, invasion and suppresses metastasis of tumors in animal models by inactivating QSOX1, an enzyme important for tumor cell growth, invasion and metastasis."

Licensing / partnership

Newly added product (GlobeNewswire) - Preclinical, Oncology

Pipeline update